Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 8/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746227 | 0.80 | FYN (0.37) | CAMKK2FYNBRD4 | |
| SCHEMBL13745693 | 0.80 | FYN (0.41) | CAMKK2FYNBRD4PTGS2MAOB | |
| SCHEMBL13745689 | 0.78 | PTGS2 (0.36) | CAMKK2FYNBRD4PTGS2MAOB | |
| SCHEMBL8313429 | 0.75 | CAMKK2 (0.63) | CAMKK2 | |
| SCHEMBL1487576 | 0.65 | HTR6 (0.45) | CAMKK2FYNBRD4PTGS2 | |
| SCHEMBL14030973 | 0.65 | FYN (0.36) | CAMKK2FYNBRD4PTGS2 | |
| SCHEMBL13609250 | 0.65 | BRD4 (0.47) | CAMKK2FYNBRD4PTGS2MAOB | |
| SCHEMBL13609200 | 0.63 | BRD4 (0.44) | CAMKK2FYNBRD4 | |
| SCHEMBL13745799 | 0.62 | BRD4 (0.41) | CAMKK2FYNBRD4PTGS2 | |
| SCHEMBL13746461 | 0.62 | CAMKK2 (0.42) | CAMKK2FYNBRD4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885FYN 259/4885BRD4 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.